ALC.SW

Alcon Inc. [ALC.SW] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ALC.SW Stock Summary

Earnings have grown 8.47% per last year.

Earnings are expected to fall -100% next year

Profit margins (0.05%) are lower than the previous year (0.1%)

Top 10 Correlated ETFs

ALC.SW

Top 10 Correlated Stocks

ALC.SW

In the News

ALC.SW Financial details

Company Rating

Buy

Market Cap

36.59B

Income

974M

Revenue

9.46B

Book val./share

Cash/share

Dividend

0.21

Dividend %

0.26%

Employees

25.32K

Optionable

Shortable

Yes

Earnings

14 May 2024

P/E

89.24

Forward P/E

PEG

14.45

P/S

4.32

P/B

2.04

P/C

P/FCF

152.85

Quick Ratio

0.89

Current Ratio

1.87

Debt / Equity

0.25

LT Debt / Equity

0.24

EPS (TTM)

1.1

EPS next Y

EPS next Q

EPS this Y

191.18%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

4.72%

Revenue Q/Q

0.99%

EPS Q/Q

SMA20

-2.72%

SMA50

12.85%

SMA100

15.6%

Inst Own

Inst Trans

ROA

ROE

ROC

0.02%

Gross Margin

55%

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

61.28-77.6

52W High

-6.34%

52W Low

+18.23%

RSI

37.08

Rel Volume

0.89

Avg Volume

833.54K

Volume

743.97K

Perf Week

-3.97%

Perf Month

-4.2%

Perf Quarter

11.61%

Perf Half Y

6.65%

Beta

0.668

Volatility

1.21%, 1.29%

Prev Close

0.17%

Price

72.12

Change

-0.58%

ALC.SW Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	15.38	14.03	16.92	17.74	19.18
Net income per share	-1.34	-1.09	0.77	0.68	1.98
Operating cash flow per share	1.88	1.69	2.74	2.48	2.82
Free cash flow per share	0.5	0.53	0.34	0.96	1.09
Cash per share	1.75	3.22	3.22	1.63	2.23
Book value per share	39.54	38.64	39.3	40.04	41.83
Tangible book value per share	0.34	1.68	3.24	2.07	5.35
Share holders equity per share	39.54	38.64	39.3	40.04	41.83
Interest debt per share	8.02	9.48	9.39	10.59	10.8
Market cap	27.75B	32.38B	43.3B	33.45B	38.49B
Enterprise value	30.74B	35.32B	46.2B	37.54B	42.53B
P/E ratio	-42.31	-60.98	115.16	99.86	39.51
Price to sales ratio	3.7	4.74	5.22	3.84	4.07
POCF ratio	30.17	39.34	32.19	27.49	27.73
PFCF ratio	113.75	126.48	262.42	70.88	71.67
P/B Ratio	1.44	1.72	2.25	1.7	1.87
PTB ratio	1.44	1.72	2.25	1.7	1.87
EV to sales	4.09	5.17	5.57	4.31	4.5
Enterprise value over EBITDA	25.07	31.68	26.3	21.83	18.54
EV to operating cash flow	33.41	42.91	34.35	30.85	30.64
EV to free cash flow	125.97	137.96	280.02	79.54	79.19
Earnings yield	-0.02	-0.02	0.01	0.01	0.03
Free cash flow yield	0.01	0.01	0	0.01	0.01
Debt to equity	0.2	0.24	0.23	0.26	0.25
Debt to assets	0.14	0.16	0.16	0.17	0.17
Net debt to EBITDA	2.43	2.64	1.65	2.38	1.76
Current ratio	1.84	2.21	2.18	1.87	2.28
Interest coverage	-1.76	-4.12	4.83	5.01	5.5
Income quality	-1.4	-1.55	3.58	3.63	1.43
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0.14	0.3	0.12
Sales general and administrative to revenue	0.38	0	0	0	0
Research and developement to revenue	0.09	0.1	0.1	0.08	0.09
Intangibles to total assets	0.69	0.65	0.63	0.64	0.61
Capex to operating cash flow	-0.73	-0.69	-0.88	-0.61	-0.61
Capex to revenue	-0.09	-0.08	-0.14	-0.09	-0.09
Capex to depreciation	-0.47	-0.35	-0.97	-0.66	-0.7
Stock based compensation to revenue	0.01	0.02	0.02	0.02	0.02
Graham number	34.57	30.78	26.05	24.78	43.12
ROIC	-0.02	-0.02	0.02	0.02	0.05
Return on tangible assets	-0.08	-0.06	0.04	0.03	0.08
Graham Net	-11.07	-10.98	-9.91	-13.05	-10.44
Working capital	1.94B	2.73B	2.91B	2.41B	3.17B
Tangible asset value	167M	820M	1.59B	1.02B	2.64B
Net current asset value	-4.12B	-3.79B	-3.36B	-4.34B	-3.34B
Invested capital	0.2	0.24	0.23	0.26	0.25
Average receivables	1.72B	1.58B	1.6B	1.75B	1.9B
Average payables	748M	854.5M	889.5M	882M	836M
Average inventory	1.47B	1.57B	1.77B	2B	2.22B
Days sales outstanding	86.83	73.82	79.86	70.6	81.45
Days payables outstanding	79.05	82.13	90.57	79.18	70.35
Days of inventory on hand	142.83	154.14	190.47	193.95	201.41
Receivables turnover	4.2	4.94	4.57	5.17	4.48
Payables turnover	4.62	4.44	4.03	4.61	5.19
Inventory turnover	2.56	2.37	1.92	1.88	1.81
ROE	-0.03	-0.03	0.02	0.02	0.05
Capex per share	-1.38	-1.16	-2.41	-1.52	-1.73

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	4.41	4.78	4.91	4.72	0
Net income per share	-0.2	0.35	0.34	0.41	0
Operating cash flow per share	0.7	0.17	0.66	0	0
Free cash flow per share	0.18	-0.04	0.42	0	0
Cash per share	1.63	1.81	1.34	0	0
Book value per share	40.01	0.04	0.04	0	0
Tangible book value per share	2.07	2.78	3.25	0	0
Share holders equity per share	40.01	0.04	0.04	0	0
Interest debt per share	10.39	9.4	9.39	0	0
Market cap	33.48B	34.88B	40.65B	38.08B	0
Enterprise value	37.57B	33.99B	39.98B	0	4.04B
P/E ratio	-86.29	50.11	60.13	46.67	0
Price to sales ratio	15.42	14.83	16.78	16.35	0
POCF ratio	97.05	410.35	125.06	0	0
PFCF ratio	372.02	-1.84K	195.41	0	0
P/B Ratio	1.7	1.74K	2.03K	0	0
PTB ratio	1.7	1.74K	2.03K	0	0
EV to sales	17.31	14.45	16.51	0	1.72
Enterprise value over EBITDA	4.17K	130.73	153.2	0	18.8
EV to operating cash flow	108.9	399.89	123.03	0	0
EV to free cash flow	417.44	-1.79K	192.23	0	0
Earnings yield	0	0	0	0.01	0
Free cash flow yield	0	0	0.01	0	0
Debt to equity	0.26	229.2	229.05	0	0.25
Debt to assets	0.17	0.16	0.16	0	0.17
Net debt to EBITDA	454.22	-3.42	-2.53	0	18.8
Current ratio	1.87	2.05	2.16	0	2.28
Interest coverage	-6.68	5.7	5.63	6.23	4.43
Income quality	-3.56	0.49	1.92	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0.69	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.09	0.09	0.09	0.09	0.09
Intangibles to total assets	0.64	0.63	0.63	0	0.61
Capex to operating cash flow	-0.74	-1.22	-0.36	0	0
Capex to revenue	-0.12	-0.04	-0.05	0	0
Capex to depreciation	-0.92	-0.35	-0.39	0	0
Stock based compensation to revenue	0.02	0.02	0.01	0	0
Graham number	13.33	0.57	0.56	0	0
ROIC	-0.03	0.05	0.05	0	0.02
Return on tangible assets	-0.01	0.02	0.02	0	0.04
Graham Net	-13.04	-15.08	-15.15	0	0
Working capital	2.41B	2.73B	2.79B	0	3.17B
Tangible asset value	1.02B	1.37B	1.6B	0	2.64B
Net current asset value	-4.34B	-4.1B	-4.07B	0	-3.34B
Invested capital	0.26	229.2	229.05	0	0.25
Average receivables	1.63B	843M	0	0	0
Average payables	857.5M	856M	876.5M	0	0
Average inventory	2.06B	2.17B	2.25B	0	0
Days sales outstanding	69.89	0	0	0	80.74
Days payables outstanding	77.41	73.15	76.66	0	68.73
Days of inventory on hand	189.62	191	192.92	0	196.78
Receivables turnover	1.29	0	0	0	1.11
Payables turnover	1.16	1.23	1.17	0	1.31
Inventory turnover	0.47	0.47	0.47	0	0.46
ROE	0	8.7	8.45	0	0.02
Capex per share	-0.52	-0.21	-0.24	0	0

ALC.SW Dividend History

ALC.SW Frequently Asked Questions

What is Alcon Inc. stock symbol ?

Alcon Inc. is a CH stock and trading under the symbol ALC.SW

What is Alcon Inc. stock quote today ?

Alcon Inc. stock price is $72.12 today.

Is Alcon Inc. stock public?

Yes, Alcon Inc. is a publicly traded company.

Something similar

Top by Market Cap

Company Profile

Volume Average 833.54K
Market Capitalization 36.59B
Employee 25.32K
CEO Mr. David J. Endicott
Headquarters Geneva,CH
IPO Date 2019-04-08
Website https://www.alcon.com

Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.